- PR Newswire•5 hours ago
Under the agreement, Sanofi will invest US$80 million in newly issued JHL shares at NT$90 per share. In addition, Sanofi will make an upfront payment of US$21 million to acquire exclusive rights for the proposed biosimilar of Rituximab and options to certain JHL pipeline products. JHL will lead the development, registration, and manufacturing activities while Sanofi will lead commercialization efforts in China.
- Investopedia•3 days ago
Two potential blockbuster drugs being developed by Regeneron and Sanofi may be delayed by deficiencies at Sanofi's manufacturing plant in France.
- PR Newswire•4 days ago
EPALINGES, Switzerland, Dec. 1, 2016 /PRNewswire/ -- Mymetics Corporation (MYMX), a pioneer and leader in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that its subsidiary Mymetics B.V. has agreed on a research project with Sanofi Pasteur, the vaccine division of Sanofi (SNY). The project will investigate the immunogenicity of influenza vaccines based on Mymetics' proprietary virosome technology platform in pre-clinical settings. "We are very excited to start this initial collaboration project with Sanofi, a world leader in the vaccine industry," said Ronald Kempers, CEO of Mymetics.
SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Bid||39.75 x 300|
|Ask||41.49 x 500|
|Day's Range||39.57 - 40.33|
|52 Week Range||36.81 - 44.50|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||23.26|
|Dividend & Yield||1.66 (4.16%)|
|1y Target Est||N/A|